 The primary purpose of this study is to characterize the acute anti-dyskinetic properties of intravenous levetiracetam in Parkinsons disease patients who have been optimized on antiparkinsonian medication. The secondary objective is to study the effect of intravenous LEV on additional motor and cognitive symptoms of PD. 